All posts related to "arthritis intel"

First of its kind study compares two RA biologic medications

“Many of our trials are done compared to placebo. However, in the office or the clinic, patients don’t want to know how the placebo works, they want to know how the drug works.”
A graphic of apples on a scale represents the comparison study of two biologic medications.
That was how Dr. Michael H. Schiff of the University of Colorado introduced the results of the first-ever two-year head-to-head comparison of two biologic treatments for rheumatoid arthritis at a press conference at EULAR 2013. Continue reading

Two new channels added to Arthritis Broadcast Network

Arthritis Broadcast Network: All your arthritis news and information. All the time.All your arthritis news and information. All the time. Share your story. Join the conversation now!

The month of September marks two milestones for arthritis in Canada: the arrival of Arthritis Awareness Month and the fifth year of the National Arthritis Awareness Program (NAAP). Since its launch, the NAAP has been creating innovative and interactive ways to broadcast the arthritis story. It continues to provide the newest arthritis information, education, programs and tools through the Arthritis Broadcast Network (ABN)—Canada’s leading online source of arthritis news.

This September, the NAAP celebrates the beginning of its fifth year with the introduction of two new exciting channels to the Arthritis Broadcast Network.

Featured ABN channels now include:

  • NAAP: National Arthritis Awareness Program *NEW*
  • Research: Groundbreaking research. Life-changing discoveries. *NEW*
  • News: Arthritis news. Anytime. Anywhere
  • Life: Living your best life with arthritis.
  • Arthritis Intel: Helping you detect, treat, and manage arthritis.
  • A-Team: Partnering with your healthcare team.
  • Women: Exploring women’s arthritis issues and needs.

We hear you. Now let the world hear you.

Join the conversation at the Arthritis Broadcast Network. Share your experience of living with arthritis by sending us your stories, videos and images, and we will share them with the world. Please email us at info@jointhealth.org. And feel free to start a conversation on ABN by commenting on a post that catches your interest.

To find out more about the NAAP, you can go to arthritisbroadcastnetwork.org or visit our Facebook page or follow us on Twitter or join us on LinkedIn.

Dr. Kam Shojania speaks about annual conference of rheumatologists

While at the 2013 Canadian Rheumatology Association Annual Scientific Meeting, the ABN interviewed rheumatologists with several questions, including about the value they get from attending this conference. Here is what Dr. Kam Shojania, ARC researcher and head of the Division of Rheumatology at the University of British Columbia, had to say.

To view more interviews, please click here.

To find out more about the event, why ABN was there, and our activities, please click here.

Êtes-vous atteint de polyarthrite rhumatoïde ?

Pour faire entendre votre voix, participez à une enquête mondiale anonyme à propos de la polyarthrite rhumatoïde (PR).

Une société internationale d’études mène une courte enquête pour recueillir de l’information chez les personnes atteintes de PR, partout dans le monde. Les résultats de cette enquête contribueront à accroître la sensibilisation mondiale à l’impact de la maladie et à mieux outiller les personnes qui souffrent de PR afin de leur permettre de gérer plus efficacement la maladie.

L’objectif de l’enquête est d’identifier comment les personnes atteintes de PR :

  • sont affectées physiquement, émotionnellement, socialement et professionnellement
  • obtiennent leur information à propos de la maladie et à quel point elles estiment cette information fiable
  • gèrent et comprennent bien leur maladie
  • établissent des relations et obtiennent un soutien des personnes de leur entourage comme leurs médecins, infirmières, amis, famille et employeurs

Toutes les réponses des participants seront intégrées et les résultats globaux seront partagés avec la grande collectivité de la PR, y compris les patients, les prestateurs de soins de santé et les groupes de défenses des patients de partout sur la planète.

Toutes les réponses demeurent anonymes.

Pour contribuer à une meilleure compréhension de la PR, faites entendre votre voix—répondez à l’enquête ici. Vous pouvez répondre à l’enquête jusqu’au 11 avril 2013.

Qu’est-ce que « PR : joignez-vous à la lutte » ?

PR : joignez-vous à la lutte est une campagne mondiale lancée par AbbVie Inc. pour accroître la sensibilisation à l’impact de la polyarthrite rhumatoïde chez les personnes qui en sont atteintes. La polyarthrite rhumatoïde est une maladie auto-immune peu reconnue, qui touche environ de 0,5 à 1 pour cent de la population. Pour mieux comprendre et faire comprendre l’impact physique et émotionnel de la PR de même que les besoins des personnes qui en souffrent, une enquête mondiale anonyme est actuellement en cours, dans 42 pays à travers le monde. Les renseignements ainsi recueillis seront utilisés par AbbVie pour la mise au point de meilleurs outils pour informer les patients, les membres de leur famille et les soignants à propos de la PR. Pour en savoir plus sur ce sujet, consultez le : www.RAJointheFight.com.

Avertissement : La mention de cette communication d’AbbVie Inc. ne constitue d’aucune manière un endossement de l’entreprise. Le comité ACE ne fait aucunement la promotion d’une « marque », d’un produit ou d’un programme dans aucun de ses matériels ou sur son site Web, ou pendant aucun de ses programmes ou activités de formation.

Celebrating World Arthritis Day

Today is World Arthritis Day and to mark the occasion, The Arthritis Society is announcing two new initiatives that will help the 4.6 million Canadians living with the disease.

Working in partnership with Pfizer Canada, The Society has launched a “Quiz to Give” fundraising campaign. From October 12 through November 12, Canadians will have the opportunity to raise $25,000 for arthritis research by putting their knowledge of arthritis to the test through a two minute online quiz.

To show its support for The Arthritis Society, Pfizer will donate $2 to The Arthritis Society for each completed quiz and Pfizer will donate an additional $2 when individuals share the quiz with family and friends.

To take the quiz and help raise $25,000 for important educational activities, please visit: arthritisquiztogive.com.

In addition, a new ANSWER tool has gone live on The Society’s website. The tool is designed to help individuals living with rheumatoid arthritis (RA) to determine if methotrexate is the right treatment option for them. The tool was created by the University of British Columbia, Arthritis Research Centre of Canada, University of Ottawa and the Centre for Digital Media.

To view the ANSWER tool please visit: arthritis.ca/ANSWER

To learn more about the ANSWER tool, tune in to the Canadian Institutes of Health Research (CIHR) Café Scientifique LIVE webcast on Tuesday, October 16 (6:00 – 8:00 p.m. PDT). www.livestream.com/w2media

Please take some time to complete the quiz and spread the word to your family and friends! Tweeting about and sharing the quiz via Facebook will help raise funds for important educational programs!

The Arthritis Newsletter, Fall Issue

Four times a year, the Consumer Advisory Board of the Arthritis Research Centre of Canada (ARC) publishes its newsletter written by arthritis patients and consumers. Highlights of the fall issue include Arthritis Awareness Month activities, study tips for students with arthritis, and staying fit. To read the articles from the newsletter, please click here or on the image below.

Two Trials Show Tofacitinib’s Potential

Tofacitinib, a potential new oral treatment for rheumatoid arthritis (RA), has shown to work as well as adalimumab in two phase III trials, though more adverse events are associated with it.

Read more: Lynda Williams, MedWire News, August 2012

Adalimumab is a tumor necrosis factor inhibitor (anti-TNF) large molecule medication taken by infusion. Tofacitinib is a Janus kinase (JAK) inhibitor. Since it is a small molecule medication, it can be made as a pill.